A detailed history of Hudson Bay Capital Management LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 345,000 shares of SAGE stock, worth $1.69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
345,000
Previous 290,700 18.68%
Holding current value
$1.69 Million
Previous $3.16 Million 21.22%
% of portfolio
0.01%
Previous 0.02%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.02 - $13.08 $381,186 - $710,244
54,300 Added 18.68%
345,000 $2.49 Million
Q2 2024

Aug 14, 2024

SELL
$10.58 - $17.9 $891,894 - $1.51 Million
-84,300 Reduced 22.48%
290,700 $3.16 Million
Q1 2024

May 15, 2024

SELL
$18.62 - $26.95 $372,400 - $539,000
-20,000 Reduced 5.06%
375,000 $7.03 Million
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $2.05 Million - $2.67 Million
120,000 Added 43.64%
395,000 $8.56 Million
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $4.36 Million - $12.7 Million
260,000 Added 1733.33%
275,000 $5.66 Million
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $2.64 Million - $3.87 Million
-65,000 Reduced 81.25%
15,000 $705,000
Q1 2023

May 16, 2023

BUY
$37.27 - $46.57 $1.17 Million - $1.46 Million
31,344 Added 64.42%
80,000 $3.36 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $8.99 Million - $11.2 Million
-241,344 Reduced 83.22%
48,656 $2.04 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $161,000 - $218,050
-5,000 Reduced 1.69%
290,000 $11.1 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $6.88 Million - $9.5 Million
250,000 Added 555.56%
295,000 $9.53 Million
Q1 2022

May 16, 2022

SELL
$30.71 - $45.71 $153,550 - $228,550
-5,000 Reduced 10.0%
45,000 $1.49 Million
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $926,500 - $1.18 Million
25,000 Added 100.0%
50,000 $2.13 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $1.01 Million - $1.43 Million
25,000 New
25,000 $1.11 Million
Q3 2020

Nov 12, 2020

SELL
$41.13 - $62.45 $6.17 Million - $9.37 Million
-150,000 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$25.95 - $43.15 $1.56 Million - $2.59 Million
60,000 Added 66.67%
150,000 $6.24 Million
Q1 2020

May 14, 2020

BUY
$26.15 - $77.24 $2.35 Million - $6.95 Million
90,000 New
90,000 $2.59 Million
Q4 2019

Feb 12, 2020

SELL
$60.18 - $154.77 $601,800 - $1.55 Million
-10,000 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$157.85 - $183.09 $1.58 Million - $1.83 Million
-10,000 Reduced 50.0%
10,000 $1.83 Million
Q4 2018

Feb 13, 2019

BUY
$81.94 - $139.71 $1.64 Million - $2.79 Million
20,000 New
20,000 $1.92 Million
Q4 2017

Feb 12, 2018

SELL
$60.72 - $167.34 $607,200 - $1.67 Million
-10,000 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$61.4 - $88.52 $614,000 - $885,200
10,000
10,000 $623,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $292M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.